Ganju, Vinod

Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer

Beer, T. M., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., Ganju, V., Polikoff, J., Saad, F., Humanski, P., et al. (2017) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 765

Atezolizumab with or without Cobimetinib versus Regorafenib in Previously Treated Metastatic Colorectal Cancer (IMblaze370): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial

Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., et al. (2019) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 577

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., Robinson, B., Broad, A., Ganju, V., Ackland, S. P., et al. (2010) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 413

1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)

Kondo, S., Yan, D., Ganju, V., Richardson, G., Hou, X., Shan, J., Liu, X., Zhang, Y., Xie, X., Xiang, Z., et al. (2023) · Annals of Oncology

Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling

Cited by 6

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer

Yamamoto, N., Yan, D., Ganju, V., Hou, X., Pan, H., Shan, J., Wang, L., Kim, S.-W., Richardson, G., Sanborn, R. E., et al. (2026) · British Journal of Cancer

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 5

Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation

Price, T., Grewal, J., Abed, A., Moore, M., Yeh, Y.-M., Gadgeel, S., Richardson, G., Underhill, C., Ganju, V., Lee, K.-W., et al. (2022) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 3